Trial Profile
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ADJUVANT
- 28 Mar 2023 Planned End Date changed from 31 Mar 2025 to 31 Jan 2026.
- 28 Mar 2023 Planned primary completion date changed from 31 Jan 2023 to 30 Apr 2025.
- 02 Jul 2020 Planned End Date changed to 31 Mar 2025.